We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Editorial |

New Insights About Hematopoietic Stem Cell Transplantation in Adrenoleukodystrophy

Hugo W. Moser, MD; Asif Mahmood, MD, MPH
Arch Neurol. 2007;64(5):631-632. doi:10.1001/archneur.64.5.631.
Text Size: A A A
Published online


Hematopoietic stem cell transplantation (HSCT) can arrest the progression of the childhood or adolescent cerebral forms of X-linked adrenoleukodystrophy (X-ALD), provided that it is administered when the disorder is still in its early stage. This was first demonstrated by Aubourg et al1 in 1990. Shapiro et al2 demonstrated that the stabilization can persist for 5 to 10 years. The most comprehensive follow-up study is that of Peters et al3 who reported on the outcome of 126 patients with childhood cerebral X-ALD who had received HSCT between 1982 and 1999. They showed that the disease stage at time of HSCT has a striking effect on outcome. Five-year survival was 92% in mildly involved patients (0 or 1 neurological deficits and a score of <9 on the 34-point magnetic resonance imaging severity score designed by Loes et al).4 In patients who underwent transplantation at a more advanced stage, 5-year survival was only 45%. Because of the paucity of historical control data for the mildly involved patients, Mahmood et al5 analyzed the survival function and clinical progression in 246 patients with childhood cerebral X-ALD who had been followed up at the Kennedy Krieger Institute during the same period and who had not received transplants. The mean 5-year survival was 54%. Patients were retrospectively assigned to the “mild” and “advanced” categories in accordance with the criteria set by Peters et al. The 5-year survival in the nontransplanted mild group was 61%, compared with 92% in the transplanted mild group. There was striking difference in functional outcome. Five years after onset, 93% of the surviving nontransplanted group had progressed severely and were totally disabled (A.M., unpublished data, 2005) whereas 53% of the transplanted “mild” group had remained entirely stable in respect to neurological and cognitive function.3 These results support the contention that HSCT benefits patients with mild cerebral involvement.

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

First Page Preview

View Large
First page PDF preview





Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.


Some tools below are only available to our subscribers or users with an online account.

2 Citations

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.

See Also...
Articles Related By Topic
Related Collections
PubMed Articles